Q-omics provides the consensus-scored GGT1 profile across patient tissues and cancer cell-line models. GGT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GGT1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GGT1 RNA expression shows 14,570 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where GGT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGT1 survival associations across molecular data types. GGT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGT1 RNA expression–survival associations across cancer types. High GGT1 expression shows unfavorable associations in UVM, ACC, BRCA and LUAD, but favorable associations in KIRC and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GGT1 RNA expression.
This table summarizes GGT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GGT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGT1 shows lower tumor expression in KICH, LUAD and LUSC and higher tumor expression in KIRC, HNSC and UCEC. The KIRC box plot shows higher GGT1 RNA expression in tumor versus normal tissue (log2 FC = +1.681, t-test p < 0.001).
This table shows molecular features associated with GGT1 in patient tissues and cancer cell lines. In patient samples, GGT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GGT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
